Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 2/20 | 0.43 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.43 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.43 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.38 |
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.38 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.38 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.38 |
| ▸ | GAPDH | P04406 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | STAT6 | P42226 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL635802 | 0.94 | PI4KA (0.40) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL2228487 | 0.90 | PI4KA (0.39) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL14586077 | 0.88 | PI4KA (0.41) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL41360 | 0.87 | PI4KA (0.55) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL13061814 | 0.87 | PI4KA (0.55) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL7186386 | 0.87 | ADORA2A (0.42) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL16258664 | 0.87 | PI4KA (0.55) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL3794703 | 0.87 | PI4KA (0.55) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL18537398 | 0.87 | PI4KA (0.55) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL18680910 | 0.87 | PI4KA (0.55) | PI4KAPI4K2BPI4K2API4KBADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1305 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119614577-A | Anti-CD 3 nucleic acid aptamer for cell targeting and labeling | 艾夏卡法国有限公司 | 2025-03-14 | — | — | CN | claimed |
| WO-2024077351-A1 | MODIFIED OLIGONUCLEOTIDES | Pharmorage Pty Limited (AU) | 2024-04-18 | — | — | WO | claimed |
| US-20220251562-A1 | Anti-CD3 Aptamers for Use in Cell Targeting and Labeling | IXAKA FRANCE (FR) | 2022-08-11 | — | — | US | claimed |
| CN-114630907-A | anti-CD 3 aptamers for cell targeting and labeling | 艾夏卡法国有限公司 | 2022-06-14 | — | — | CN | claimed |
| EP-4004209-A2 | ANTI-CD3 APTAMERS FOR USE IN CELL TARGETING AND LABELING | IXAKA FRANCE (FR) | 2022-06-01 | — | — | EP | claimed |
| WO-2021019301-A2 | ANTI-CD3 APTAMERS FOR USE IN CELL TARGETING AND LABELING | ARATINGA.BIO ACI (FR) | 2021-02-04 | — | — | WO | claimed |
| WO-2017189528-A1 | CORROSION INHIBITOR COMPOSITIONS AND METHODS OF USING SAME | Ecolab USA, Inc. (US) | 2017-11-02 | — | — | WO | claimed |
| CN-106232834-A | Sample preparation methods | 牛津纳米孔技术公司 | 2016-12-14 | — | — | CN | claimed |
| EP-2710136-A1 | ENGINEERED NUCLEIC ACIDS AND METHODS OF USE THEREOF FOR NON-HUMAN VERTEBRATES | Moderna Therapeutics, Inc. (US) | 2014-03-26 | — | — | EP | claimed |
| WO-2013177222-A1 | METABOLITE BIOMARKERS FOR THE DETECTION OF LIVER CANCER | PURDUE RESEARCH FOUNDATION (US) | 2013-11-28 | — | — | WO | claimed |
| CN-102762215-A | HBV antisense inhibitors | GLAXO GROUP LTD | 2012-10-31 | — | — | CN | claimed |
| EP-2512491-A1 | HBV ANTISENSE INHIBITORS | Glaxo Group Limited (GB) | 2012-10-24 | — | — | EP | claimed |
| WO-2011047312-A1 | HBV ANTISENSE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2011-04-21 | — | — | WO | claimed |
| US-20100254901-A1 | Compositions comprising nucleic acid aptamers | SMITH CASSANDRA L | 2010-10-07 | — | — | US | claimed |
| US-20070082863-A1 | Methods and compositions for maturing dendritic cells utilizing inosine-containing compounds | IRX THERAPEUTICS, INC. | 2007-04-12 | — | — | US | claimed |
| EP-1485395-A2 | NUCLEOTIDE MIMICS AND THEIR PRODRUGS | Biota, Inc. (US) | 2004-12-15 | — | — | EP | claimed |
| WO-2003072757-A9 | NUCLEOTIDE MIMICS AND THEIR PRODRUGS | BIOTA INC (US) | 2004-10-21 | — | — | WO | claimed |
| WO-2003072757-A2 | NUCLEOTIDE MIMICS AND THEIR PRODRUGS | BIOTA, INC. (US) | 2003-09-04 | — | — | WO | claimed |
| US-5075225-A | PROCESS FOR THE ENZYMATIC SYNTHESIS OF NUCLEOSIDES | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 1991-12-24 | — | — | US | claimed |
| EP-0391592-A1 | Process for the enzymatic synthesis of nucleosides | THE TEXAS A & M UNIVERSITY SYSTEM (US) | 1990-10-10 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082863-A1 | Methods and compositions for maturing dendritic cells utilizing inosine-containing compounds | INMT, STING1, ITPA | PI4KA 1797/4885PI4K2B 2019/4885PI4K2A 1848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.